Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by westcoast1000on Apr 17, 2023 12:43am
188 Views
Post# 35397817

RE:RE:RE:RE:Merck to buy Prometheus Bio....

RE:RE:RE:RE:Merck to buy Prometheus Bio.... "the investgators said they did not have trouble recruiting candidates so this wasn't the reason for the smal number, which is not statistical significant."

Are you referring to the Goblet trials? We do not yet have results on PFS or OS. Those come after everyone on the trial progresses. 

Whether the results are statistically significant cannot be answered without the tests being done. The samples in each of the arms are relatively small as you note. They add up to roughly 50. But the purpose of those results is not to be the definitive nail to pin down an approval. That comes in the next trial.

The early days of this company are effectively a different company. They are now doing something entirely different, that was largely unknown to science and seen as fringe activity 20 years ago. So drawing conclusions by generalizing from what happened before they started on the I/O road instead of direct lysis really does not lend any insight.

I think there were lots of good reasons why they attracted no attention in the period from about 5 to 20 years ago. One would be Brad T., second would be coming from Canada, third is they had a weird approach compared to the standard poisons, fourth they did not have really good results until they started doing combo treatments.

Rest assured, I want this company to work as much or more than anyone else. I just say it is obvious they have something valuable in their virus itself, not for killing cancer but for the effect on the immune system. And I do not buy the idea there is some hidden fatal flaw we do not know about.
the results of last fall belie that notion.

They have not had the money to run big trials, nor the expertise, nor the connections with partners to make progress like a well funded small biotech.

But that has meant you can buy a big part of the company for not a huge amount of money. 



<< Previous
Bullboard Posts
Next >>